Wolff-Parkinson-White — chronic risk stratification
Pre-excitation pathway · Cardiac
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Wolff-Parkinson-White describes ventricular pre-excitation via an accessory pathway with symptomatic tachyarrhythmia. Chronic management risk-stratifies the pathway's conduction properties because a rapidly conducting pathway during AF can degenerate into ventricular fibrillation.
Red flags
- Pre-excited atrial fibrillation (broad, irregular, very fast)
- Syncope in a patient with pre-excitation
- Shortest pre-excited RR interval <250 ms on EP study
- Family history of sudden death with pre-excitation
- Multiple accessory pathways
Assessment
Differential diagnosis
- AVNRT
- Concealed accessory pathway (orthodromic AVRT)
- Atrial fibrillation with aberrancy
- Fasciculoventricular pathway
- Ventricular tachycardia
- Mahaim fibre tachycardia
Investigations
- 12-lead ECG (delta wave, short PR, wide QRS)
- Ambulatory ECG for intermittent pre-excitation
- Exercise test (abrupt loss of pre-excitation suggests low-risk pathway)
- Echocardiogram (associated Ebstein anomaly)
- Electrophysiology study with pathway refractory period assessment
- Thyroid function if palpitations
Management
- Confirm pre-excitation and document any tachyarrhythmias
- Distinguish WPW syndrome (pre-excitation plus arrhythmia) from an asymptomatic pattern
- Assess accessory-pathway risk, especially the shortest pre-excited RR in AF
- Offer electrophysiology study and catheter ablation to symptomatic patients
- Consider EP study in asymptomatic high-risk occupations or athletes
- Ablate accessory pathways with high success and low complication rates
- Avoid AV nodal blockers (adenosine, verapamil, diltiazem, digoxin) in pre-excited AF
- Use procainamide or electrical cardioversion for pre-excited AF emergencies
- Counsel on symptoms of rapid palpitations and syncope
- Reassess pathway risk if symptoms develop in a previously asymptomatic patient
- Provide driving and sports advice per pathway risk and arrhythmia history
- Arrange follow-up to confirm ablation success
Drugs & doses
Flecainide 50-150 mg PO BD (pathway-modifying antiarrhythmic if ablation declined, no structural disease)
Procainamide 10-15 mg/kg IV over 20-30 min for pre-excited AF (acute)
Sotalol 80-160 mg PO BD as an alternative antiarrhythmic
Avoid: verapamil, diltiazem, digoxin, adenosine in pre-excited AF
Disposition
Refer to electrophysiology for risk stratification and ablation. Asymptomatic low-risk patterns may be observed with counselling.
Complications & pitfalls
- Sudden cardiac death from pre-excited AF degenerating to VF
- Recurrent AVRT
- Atrial fibrillation
- Ablation-related AV block (septal pathways)
- Tachycardia-mediated cardiomyopathy
Exam pearls
- Loss of pre-excitation at higher heart rates on exercise indicates a lower-risk pathway
- Catheter ablation is curative and first-line for symptomatic WPW
- Never give AV nodal blockers for pre-excited AF — they can accelerate ventricular rates
- A truly asymptomatic WPW pattern has a low but non-zero sudden-death risk
- Associated Ebstein anomaly warrants echocardiography
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.